Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb sutertinib maleate in advanced or metastatic EGFR rare-mutation NSCLC
ChiCTR2100051136Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sutetinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Objective response rate, Disease control rate and 7 more. Started Sep 2021; status: recruiting.
02
Drugs
sutetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100051136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051136.